Advancing Novel Therapies for Inflammatory Diseases
Joined March 2022
- Tweets77
- Following50
- Followers75
- Likes2
"GPCR targeting represents approximately 35% of all approved drugs and account for neurological indications such as ..." A true leap forward in MOA understanding for a biotherapeutic! [LPA3 agonism] #Parkinsons #MultipleSclerosis #Neuroscience
Adiso Therapeutics retweeted
発酵食品やヨーグルトに含まれる乳酸菌がストレスへの抵抗力と抑うつ・不安予防に役立つことを示唆する論文。バージニア大学の研究によれば、乳酸菌は免疫機能を調整して気分に影響を及ぼし、抑うつや不安などのメンタルヘルスの予防・治療に役立つ可能性が示された。
(Brain Behavior and Immunity)
Team @AdisoTx thrilled with latest ADS024 publication - an oral single strain live biotherapeutic (SS-LBP) This research highlights the potential role of ADS024 for neuroinflammatory conditions #MS #Parkinson #FA #Huntingtons #Patientsfirst #neuroinflammaiton @UCC #GCPR #ALS
Adiso Therapeutics retweeted
Good luck to @UCC spinout @AdisoTx at the @KTIconnect Awards tonight. We sat down with Professor Paul Ross, one of the founders of @AdisoTx, to discuss the history of @AdisoTx & its achievement of being shortlisted for the commercialisation award – bit.ly/3Vlz6TG
Adiso Therapeutics retweeted
@KTIconnect awards have just started. Good luck to all those short listed, especially @UCC and @Pharmabiotic spin- out company @AdisoTx shortlisted for the Commercialisation Award #ktiawards
Adiso Therapeutics retweeted
Great to see Michéal and Kathriona at this important event. We’ll done everyone.
Adiso Therapeutics retweeted
Interesting: @parasmin et al report inhibition of indoleamine-2,3-dioxygenase 1 (IDO1) & production of kynurenine rescues hippocampal synaptic plasticity & memory function in models of amyloid & tau pathology (via astrocytic metabolic support of neurons)
science.org/doi/10.1126/scie…
Adiso Therapeutics retweeted
Interesting: Adiso Therapeutics @AdisoTx researchers present a LPA3 agonist-producing Bacillus velezensis (called ADS024) whose anti-neuroinflammatory properties corrects multiple models of #Parkinsons (& #MultipleSclerosis, #Huntingtonsdisease, #ALS, etc)
sciencedirect.com/science/ar…
Adiso is developing ADS051 to provide patients a new treatment opportunity. We believe this mission is fulfilled by keeping #patientsfirst. Listen to our recent podcast with @rahulc of the @Biotech2050Pod t.ly/lF_JG
#Leadership
#IBD
#ulcerativecolitis
Join host @rahulc in the latest episode of the Biotech2050 podcast with Scott Megaffin, CEO of @AdisoTx, as they discuss differentiation and collaboration in the biotech industry
Listen to the episode: t.ly/lF_JG
We look forward to participating in the virtual @CG_Driven Inflammatory Bowel Disease Symposium this Wednesday. Tune in to the “Emerging Novel Targets in IBD” panel to hear Adiso CEO Scott Megaffin discuss our highly differentiated approach to treating #inflammatorydiseases.
From the Adiso team to you, have a safe and happy #holidayseason. As we approach the new year, we’d like to reflect on our 2023 milestones and express gratitude to all who have contributed to our achievements. May your time with friends and family be filled with joy.
Connect with Adiso at #BiotechShowcase in San Francisco next month! Get in touch with us directly at [email protected] or through the partnering platform to schedule a meeting: bit.ly/3thApub
#Inflammatorydisease
#Ulcerativecolitis
#Biotech
Adiso is pleased to announce a Precision Immunology collaboration with @GeneoscopyCo investigating therapeutic options for patients with #IBD. Employing #RNA biomarker technology developed by Geneoscopy in conjunction with ADS051. Learn more: bit.ly/3TbtFJ0
Today kicks off Crohn’s & Colitis Awareness Week. Year-round, we are dedicated to advancing research and development of novel therapies for patients with #ulcerativecolitis and other #inflammatorydiseases. Read about our progress: bit.ly/47RLUao #IBDVisible
We wish a happy Thanksgiving to all, with gratitude for the courageous patients who participated in Adiso clinical trials, as well as our advisors and partners for their guidance and unwavering support. From our team to you, have a healthy and happy #Thanksgiving! #PatientsFirst
We’re excited to participate in the @WellsFargo 2023 Virtual Private Biotech Symposium, fresh off the heels of our positive topline data announcement from our Phase 1b study of ADS051! Connect with us to learn about our great progress.
#ulcerativecolitis
#inflammatorydisease
Our team was overjoyed to unveil positive topline data from our Phase 1b MAD study highlighting the potential of ADS051 as a safe and effective therapy for #ulcerativecolitis. We’re excited to advance ADS051 in a Phase 2 trial. Learn more: bit.ly/46X4Yn5
It’s with great pleasure that we announce positive topline data presented at #ACG2023 from our Phase 1b MAD study of ADS051, a first-in-class, oral, gut-restricted, small molecule neutrophil modulator for #ulcerativecolitis! Read the release: bit.ly/46X4Yn5
We’re delighted to welcome Robert Lisicki, an accomplished #biopharma industry executive, to our Board of Directors! Rob’s expertise will be an integral resource as we advance our neutrophil modulator, ADS051, to Phase 2 for #IBD. Learn more: bit.ly/45sz5S3
Major milestone alert! We’re thrilled to present data from our Phase 1b MAD study of ADS051 for moderate-to-severe ulcerative colitis this month at #UEG2023 and #ACG2023. More details to come!
@my_ueg Week 2023
@AmCollegeGastro 2023 Annual Scientific Meeting